Trial Profile

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezuclastinib (Primary) ; Sunitinib (Primary)
Indications Gastrointestinal stromal tumours
Focus Pharmacokinetics; Registrational; Therapeutic Use
Acronyms PEAK
Sponsors Cogent Biosciences

Most Recent Events

16 Jun 2026 Status changed from active, no longer recruiting to recruiting.
30 May 2026 According to a Cogent Biosciences media release, full results from this PEAK trial were presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
30 May 2026 Results presented in the Cogent Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com